Smith+Nephew

Investor presentation
November – December 2026



Forward looking statements and non-IFRS measures

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. The terms ‘Group’ and ‘Smith+Nephew’ are used for convenience to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

Certain items included in ‘trading results’, such as trading profit, trading profit margin, trading attributable profit, tax rate on trading results (trading tax expressed as a percentage of trading profit before tax), Adjusted Earnings Per Ordinary Share (EPSA), trading cash flow, free cash flow, trading profit to trading cash conversion ratio, leverage ratio, and underlying revenue growth are non-IFRS financial measures. The non-IFRS financial measures in this announcement are explained and, where applicable, reconciled to the most directly comparable financial measure prepared in accordance with IFRS in our Second Quarter and Half Year 2026 Results announcement dated 4 August 2026.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

Our 170 year history

1856
Smith+Nephew established

1856-1896
Thomas James Smith opened a chemist shop in Hull, UK and develops a new method for refining cod liver oil. In 1896 Horatio Smith entered a partnership with his uncle forming TJ Smith & Nephew



1914
Days after the outbreak of WW1, we received an order to provide surgical and field dressing supplies to French army within 5 months





During WW1, staff grew from 50 to 1,200



From 50
To 1200



1928
We produced an experimental bandage Elastoplast™

1937
We were listed on the London stock exchange



1937
We developed a special low-temperature plaster for the Everest climbers on the 1953 expedition. It enabled them to send back camera films, sealed and airtight!.



1986
Key acquisitions of Richards Medical in Memphis, specialists in orthopaedic products and DYONICS, an arthroscopy specialists based in Andover



1995
Acquired Acufex Microsurgical Inc, making us a market leader in arthroscopic surgical devices





1999
We were listed on the New York Stock Exchange and in 2001 became a constituent member of the UK FTSE-100 index



2001
Introduced OXINIUM◇, a new material that improves performance and increases the service life of total joint replacement systems



2011
PICO◇, the first pocket-sized, single-use system, revolutionizes the negative pressure wound therapy market




2013
JOURNEY◇ II BCS sets a new standard in knee implant performance, designed to empower patients



2014
Acquired Arthrocare Corp. to expand our sports medicine portfolio

2015
Acquired Blue Belt Technologies securing a leading position in orthopaedic robotics-assisted surgery



2017
Acquired tissue regeneration developer Rotation Medical



2019
Expanding in technologies of the future, we acquired:
- Osiris Therapeutics
- Ceterix Orthopaedics
- Leaf Patient Monitoring System
- Brainlab Orthopaedic Joint Reconstruction Business



2020
Acquired Tusker Medical Inc. to expand even more our ENT medicine portfolio




2020
Launched Real Intelligence and CORI◇ Surgical System; next generation handheld robotics platform





2024
Acquired CartiHeal developer of novel technology for cartilage regeneration



2026
Acquired Integrity Orthopaedics, manufacturer of novel approach to rotator cuff repair

~17,000 employees over 100 Countries



Today

We exist to restore people's bodies and their self-belief by using technologies to take the limits off living. We call this purpose
"Life Unlimited"

Well positioned in attractive markets worth c.$50bn, growing 6%[1]


Advanced Wound Management



$13bn

S+N #2 player
13% share

Orthopaedics[2]



$33bn

S+N #4 player
7% share


Sports Medicine



$7bn

S+N #2 player
25% share

Ear, Nose and Throat



$2bn

S+N joint #4 player
9% share

1. Internal estimates using Smart Track, IQVIA
2. Hips, knees, trauma, extremities and robotics

Strong, diversified portfolio across product categories



ALLEVYN◇ LIFE
Advanced Foam
Wound Dressings

Advanced Wound Care



Collagenase
SANTYL◇ Ointment
Enzymatic debrider

Advanced Wound Bioactives

ENT



COBLATION◇
Wand

Arthroscopic Enabling Technologies




REGENETEN◇
Bioinductive Implant

Sports Medicine Joint Repair

Other Recon

CORI◇
Surgical
System





Advanced Wound Devices

PICO◇
Negative Pressure
Wound Therapy



Knees

JOURNEY◇ II TKS
LEGION◇ TKS




Hips

CATALYSTEM◇
OR3O◇
Dual Mobility



Trauma & Extremities

EVOS◇
Plating System
AETOS◇ Shoulder
System




Q3 2026 revenue

Q3 2026 summary revenue performance


Total revenue of $1,551m

- Underlying revenue growth of +3.4%; reported 3.4%
- Same number of trading days vs Q3 2025
- No impact from FX on reported growth

Growth by Business Unit*



Growth by Region*




* Growth rates are versus Q3 2025 on an underlying basis

Sports Medicine & ENT

Strong growth in Joint Repair and AET; ENT impacted by China VBP as expected

Revenue of $507m:
+7.9% underlying*; +8.0% reported



Q3 sales factors

- **Sports Medicine Joint Repair +11.2%:**
  - Continued strong growth from core portfolio and REGENETEN™
  - Growth well balanced across all regions
- **AET +7.5% (+8.7% ex China):**
  - Strong performance in FASTSEAL™ and Services
  - Double-digit growth in US offsetting China weakness ahead of VBP
- **ENT -5.6% (+10.0% ex China):**
  - Strong growth in the US and International driven by Nose and Throat
  - Inventory channel reductions in China ahead of VBP implementation

RISE: 2026 drivers


- Drive further market penetration of REGENETEN
- Capitalise on strength of shoulder portfolio
- Launch TESSA™, our first-in-industry spatial surgery arthroscopic platform

* Growth rates are versus Q3 2025

Advanced Wound Management

Strong acceleration in AWD and solid growth in AWC; AWB impacted by US reimbursement change

Revenue of $454m:
-0.2% underlying*; 0.0% reported



Q3 sales factors

- **Advanced Wound Care +1.2%:**
  - Above market growth in foam dressings
  - Double digit growth in US ALLEVYN™, led by ALLEVYN COMPLETE CARE
- **Advanced Wound Bioactives -8.8%:**
  - SANTYL™ returned to modest growth
  - Skin substitutes stable sequentially despite US reimbursement headwind
- **Advanced Wound Devices +10.7%:**
  - Strong growth in PICO™ in the US and internationally
  - LEAF™ Patient Monitoring System continues to see strong uptake

RISE: 2026 drivers


- Take share with ALLEVYN COMPLETE CARE
- Navigate CMS reimbursement change to skin substitutes and prior authorisation in SANTYL
- Access new settings and patient populations with products including PICO and LEAF

* Growth rates are versus Q3 2025

Orthopaedics

Returned to growth, with international strength offsetting weaker performance and market in US Knees and US Hips

Revenue of $590m:
+2.5% underlying*; +2.3% reported



Q3 sales factors

- **Global Knees and Hips -2.0% and +2.0%:**
  - **US Hips -1.0%;** CATALYSTEM™ momentum tempered by pace of set deployment, and **Knees -7.3%;** continued effect of portfolio mix relative to market demand
  - **OUS Hips +6.0%;** strong performance across International and Emerging Markets, and **Knees +4.0%;** good growth in Emerging Markets
- **Trauma & Extremities +1.8%:**
  - Strength in AETOS™ and IM Nails
  - Double digit growth in Emerging Markets
- **Other Reconstruction +44.7%**, strong growth in placements globally and continued strong progress in enterprise deals in the US

RISE: 2026 drivers

- Drive growth with CORI™, supported by launch of Shoulder
- Execute initial launch of LANDMARK™ knee
- Deliver operational efficiencies with Ortho 360 operational model

* Growth rates are versus Q3 2025
** Other Recon includes robotics capital sales, joint navigation and bone cement

Updated 2026 guidance

c.3%
revenue growth*

c.4%
trading profit growth*

c.$1.25b
trading profit
incl marginal Integrity dilution



c.$750m
FCF

c.9%
ROIC*

Revenue growth given on an underlying basis and trading profit growth on a reported basis
*Excluding M&A



RISE Strategy

Sports Medicine & ENT: Leading positions in large, attractive markets

Strong leadership position…

- A leading position in a market worth c.$7.0 billion, growing c.6% annually
- #1 or #2 position in every major segment we compete in
- Creating new categories with Big Four: REGENETEN, CARTIHEAL™ AGILI-C™, TENDON SEAM and TESSA
- Opportunity to deliver sustained above-market growth, underpinned by strong core portfolio and the Big Four

…With multiple drivers of growth

	Recent Key Launches	2027- 2028*
Joint Repair	 REGENETEN Clinical evidence  CARTIHEAL AGILI-C  Q-FIX™ KNOTLESS  TENDON SEAM™	 NextGENETEN
AET	 TESSA Femur  Flow FLEXTEND™	 TESSA Tibia
ENT	 TULA™  WEREWOLF™ COBLATION™ System  LYNX™ COBLATION Laryngeal Wand	 PHOENIX™ Next Gen Controller  PHOENIX AURA™ CIT Wand



*pending regulatory clearance

AWM: Strong position in fragmented market

Strength and breadth across portfolio…

- Large and attractive market worth c.$13.1b
- Hold #1 or #2 position across the 3 segments of the wound market
- Broad portfolio to participate in highest growth markets
- Opportunity to expand our participation in attractive segments

…With continued investment in innovation

	Recent Key Launches	2027- 2028*
AWC	 ALLEVYN AG+  ALLEVYN COMPLETE CARE	 Next Gen ALLEVYN Gentle Border
AWB	 BIOBRANE™ US  GRAFIX™ PLUS	 Synthetic Scaffold
AWD	 LEAF 3.0  PICO New Sizes  RENASYS™ Abdo Shield  RENASYS WOUND+	 LEAF Releases  PICO Protect FLEX





*pending regulatory clearance

Ortho: Strengthened business entering next product cycle

Stronger as a result of 12-PP…

- Global Business Unit alignment
- Operational transformation
- Right-sized manufacturing capacity
- Improved inventory health
- Rewired commercial engine
- Tighter performance management
- Refocused innovation and improved execution
- Established launch excellence process


…With further progress to come as launches scale

	Recent Key Launches	2027- 2028*
Knee	 LEGION™ MS Inserts  CORI XT KNEE  LANDMARK Knee CR Porous	 LANDMARK Knee CR Cemented  CORI KNEE (CT)
Hip	 CORIOGRAPH™ Hip  CATALYSTEM Hip System	 CORI XT HIP Robotic System  CORI XT HIP Impactor
Shoulder	 AETOS Shoulder  CORIOGRAPH Shoulder  CORI XT SHOULDER (AETOS)	 AETOS CONCELOC Glenoid
Trauma	 EVOS™ Patella  TRIGEN™ MAX Tibia Nailing System  EVOS Pelvic  INTERTAN™ MAX Hip Fracture Nail	 INTERTAN MAX (Retrograde & Antegrade)

*pending regulatory clearance

Key messages

- Underlying Q3 revenue growth accelerated from Q2, with strength in Sports, improved performance in Wound and return to growth in Orthopaedics
- Sustained innovation driving growth across the portfolio with >50% of our growth coming from products launched within the last 5 years
- Updating full year guidance to reflect trading in US Recon and now expect c.3% revenue growth, c.$1.25b trading profit, with profit growth still ahead of revenue growth as operational improvements flow through to P&L, and c.$750m FCF, reflecting strong cash conversion
- Focused on driving shareholder value through investing in Sports and Wound and exploring the full range of options for Orthopaedics, while also executing on product launches



Appendix

Technical guidance for FY 2026

	November 2026	
Foreign exchange and acquisitions		
Translational FX impact on revenue growth[1]	c.1.0%	
Acquisition impact on revenue growth	-	
Non-trading items		
Restructuring costs	c.$70m	
Acquisition and integration	c.$85m	
Other	**Adjusted**	**Reported**
Amortisation of acquisition intangibles	$165-175m	$165-175m
Income/(loss) from associates[2]	$15-20m	$10-15m
Net interest[3]	c.$125m	c.$125m
Other finance costs	$10-15m	$15-20m
Tax rate on trading result	19-20%	
Dividend payout ratio	35-40%	

(1) Based on the foreign exchange rates prevailing on 30 October 2026
(2) Based on analyst consensus forecasts for associate, sourced from Capital IQ on 22 October 2026 and considering management guidance issued on 02 November 2026
(3) Includes interest associated with IFRS 16 Leases

Revenue analysis by Business Unit

	2025					2026			
	Q1 Growth %	Q2 Growth %	Q3 Growth %	Q4 Growth %	Full Year Growth %	Q1 Growth %	Q2 Growth %	Q3 Growth %	Q3 Revenue $m
Orthopaedics	**3.2**	**5.0**	**4.1**	**7.9**	**5.1**	**0.8**	**(1.0)**	**2.5**	**590**
Knee Implants	0.7	2.9	1.5	6.1	2.9	(2.8)	(4.3)	(2.0)	229
Hip Implants	(1.2)	3.4	3.7	5.7	2.9	4.1	0.5	2.0	157
Other Reconstruction	46.6	39.8	9.7	40.8	33.8	6.0	0.8	44.7	41
Trauma & Extremities	6.3	4.4	7.5	6.9	6.3	2.4	2.4	1.8	163
Sports Medicine & ENT	**2.4**	**5.7**	**5.1**	**7.3**	**5.2**	**6.7**	**8.6**	**7.9**	**507**
Sports Medicine Joint Repair	2.9	8.4	8.6	10.9	7.8	10.0	10.6	11.2	283
Arthroscopic Enabling Technologies	(0.1)	2.3	0.2	3.4	1.6	6.7	8.8	7.5	169
ENT	7.8	3.6	4.3	2.3	4.4	(9.4)	(1.6)	(5.6)	55
Advanced Wound Management	**3.8**	**10.2**	**6.0**	**2.8**	**5.6**	**2.2**	**(2.1)**	**(0.2)**	**454**
Advanced Wound Care	2.5	2.6	1.1	4.4	2.6	4.9	3.7	1.2	200
Advanced Wound Bioactives	(2.0)	18.6	12.2	(0.5)	6.8	(1.7)	(12.7)	(8.8)	144
Advanced Wound Devices	15.7	12.7	6.7	5.4	9.8	1.9	3.8	10.7	110
Total	**3.1**	**6.7**	**5.0**	**6.2**	**5.3**	**3.1**	**1.6**	**3.4**	**1,551**

All revenue growth rates are on an underlying basis and without adjustment for number of selling days.

Quarterly revenue analysis by region

	2025					2026			
	Q1 Growth %	Q2 Growth %	Q3 Growth %	Q4 Growth %	FY Growth %	Q1 Growth %	Q2 Growth %	Q3 Growth %	Q3 Revenue $m
US	3.6	8.7	5.5	5.6	5.9	2.1	(1.3)	3.0	812
Other Established Markets(1)	5.0	7.4	3.9	7.2	5.9	1.0	1.7	3.2	456
Established Markets	**4.1**	**8.2**	**4.9**	**6.2**	**5.9**	**1.7**	**(0.2)**	**3.1**	**1,268**
Emerging Markets	(1.7)	(0.2)	5.4	6.4	2.5	10.5	10.6	4.8	283
Total	**3.1**	**6.7**	**5.0**	**6.2**	**5.3**	**3.1**	**1.6**	**3.4**	**1,551**

(1) Other Established Markets are Australia, Canada, Europe, Japan and New Zealand.
All revenue growth rates are on an underlying basis and without adjustment for number of selling days

Q3 consolidated revenue analysis by Business Unit

	Q3 2026 $m	Q3 2025 $m	Reported growth %	Underlying growth %	Acquisitions/disposals %	Currency impact %
Orthopaedics	**590**	**577**	**2.3**	**2.5**	**-**	**(0.2)**
Knee Implants	229	235	(2.6)	(2.0)	-	(0.6)
Hip Implants	157	154	1.9	2.0	-	(0.1)
Other Reconstruction	41	29	43.8	44.7	-	(0.9)
Trauma & Extremities	163	159	2.3	1.8	-	0.5
Sports Medicine & ENT	**507**	**469**	**8.0**	**7.9**	**-**	**0.1**
Sports Medicine Joint Repair	283	255	11.1	11.2	-	(0.1)
Arthroscopic Enabling Technologies	169	157	7.7	7.5	-	0.2
ENT	55	57	(4.8)	(5.6)	-	0.8
Advanced Wound Management	**454**	**455**	**(0.0)**	**(0.2)**	**-**	**0.2**
Advanced Wound Care	200	197	1.4	1.2	-	0.2
Advanced Wound Bioactives	144	158	(8.7)	(8.8)	-	0.1
Advanced Wound Devices	110	100	10.7	10.7	-	0.0
Total	**1,551**	**1,501**	**3.4**	**3.4**	**-**	**0.0**


Trading days per quarter

	Q1	Q2	Q3	Q4	Full year
2024	63	64	63	62	252
2025	62	63	63	63	251
2026	**61**	**63**	**63**	**64**	**251**
2027	64	64	63	60	251

Our capital allocation framework

1. Invest

- Innovation to drive a step-up in organic growth



2. Acquire

- New technologies and expand in high growth segments with strong strategic fit that meet our financial criteria
- Accretive to group revenue growth
- NPV positive

4. Return

- Surplus capital to shareholders
- $500m share buyback in 2025

3. Maintain

- Optimal balance sheet position
- Investment grade credit ratings
- Target leverage ratio of around 2x
- Willing to accept higher leverage for acquisitions, returning to target within 18-24 months
- Dividend: Progressive with a payout ratio of around 35% - 40%